Clinical Trial

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB3008 as monotherapy in subjects with advanced solid tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-19.
Status change: Recruiting → Active, Not Recruiting 2025-11-14
Trial Details
NCT Number NCT06143007
Lead Sponsor Broadenbio Ltd., Co.
Conditions Advanced Solid Tumor
Enrollment 42 participants
Start Date 2023-10-26
Primary Completion 2025-05-22 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-17